Regulatory Considerations for Controlling Intermediates in Type-II Drug Master Files for the Manufacture of Generic Drug Substances

Publication
Article
Pharmaceutical TechnologyPharmaceutical Technology-03-15-2016
Volume 2016 eBook
Issue 1
Pages: s46-s54

The authors present analysis of the state of control of intermediate identity and quality, based on analysis of recently submitted DMFs.

The authors present analysis of the state of control of intermediate identity and quality, based on analysis of recently submitted DMFs.

Read this article

from Pharmaceutical Technology’s 2016 Solid Dosage Drug Development and Manufacturing eBook.

View other articles in the

2016 Solid Dosage Drug Development and Manufacturing eBook.
Recent Videos
Buy, Sell, Hold: Cell and Gene Therapy
Buy, Sell, Hold: Cell and Gene Therapy
Related Content